Same ingredient, two names · semaglutide
Ozempic vs Wegovy
From the two FDA labels, read Published by PepVault
Ozempic and Wegovy are the same medicine, semaglutide, under two names from Novo Nordisk.
What differs is the label. FDA approved Ozempic for blood sugar control in adults with type 2 diabetes, and lowering heart and kidney risks in some of them. Wegovy is approved for weight loss and keeping it off, lowering heart risk in adults with heart disease and excess weight, and (the injection) the liver disease MASH.
Label against label
| Compared | Ozempic | Wegovy |
|---|---|---|
| Active ingredient | semaglutide | semaglutide |
| Class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Maker | Novo Nordisk | Novo Nordisk |
| Approved for | Type 2 diabetes; heart and kidney risk in type 2 diabetes | Weight reduction; heart risk with obesity; MASH (injection) |
| Forms | Multi-dose pen; Single-dose prefilled syringe; Tablet | Single-dose pen; Single-dose syringe; FlexTouch pen; Tablet |
| How often | once a week or once a day | once a week or once a day |
| Starting dose | 0.25 mg a week (injection); 1.5 mg a day (tablets) | 0.25 mg a week (injection); 1.5 mg a day (tablets) |
| Top dose on the label | 2 mg a week (injection); 9 mg a day (tablets) | 7.2 mg a week (injection); 25 mg a day (tablets) |
| Most reported side effect | Nausea, 20.3% on 1 mg (placebo 6.1%) | Nausea, 44% on 2.4 mg (placebo 16%) |
| Boxed warning | “RISK OF THYROID C-CELL TUMORS” | “RISK OF THYROID C-CELL TUMORS” |
| First approved | 2017 | 2021 |
Each label’s side-effect figure comes from its own trials, at its own doses and in its own patients; as the labels themselves say, rates from different trials can’t be compared directly.
The two dosing schedules
This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.
Ozempic injection, once a week
Ozempic tablets, once a day
Wegovy injection, once a week
Wegovy tablets, once a day

A missed dose, on each label
- Ozempic: A missed weekly injection is taken as soon as possible within 5 days. Past 5 days, the label skips it and the next dose comes on the usual day.
- Wegovy: For a missed injection, the label looks at the next scheduled dose: more than 2 days away, take the missed one as soon as possible; less than 2 days away, skip it. Missing 2 or more weeks in a row means starting the climb again from a lower dose.
The research on the ingredient
Questions
Are Ozempic and Wegovy the same drug?
They hold the same active ingredient, semaglutide, from Novo Nordisk. They are approved for different uses and come in different forms and doses.
What are Ozempic and Wegovy approved for?
Ozempic is approved for blood sugar control in adults with type 2 diabetes, and lowering heart and kidney risks in some of them. Wegovy is approved for weight loss and keeping it off, lowering heart risk in adults with heart disease and excess weight, and (the injection) the liver disease MASH.
How often are Ozempic and Wegovy taken?
Ozempic is taken once a week or once a day, as an injection or a tablet; Wegovy once a week or once a day, as an injection or a tablet.
What are the dose ranges of Ozempic and Wegovy?
On their labels, Ozempic runs 0.25 mg to 2 mg once a week or 1.5 mg to 9 mg once a day, and Wegovy 0.25 mg to 7.2 mg once a week or 1.5 mg to 25 mg once a day. A prescriber sets the actual dose.
What is the most common side effect of Ozempic and Wegovy?
On Ozempic’s label: nausea, 20.3% on 1 mg (placebo 6.1%). On Wegovy’s: nausea, 44% on 2.4 mg (placebo 16%).
Sources
- OZEMPIC (semaglutide) injection, for subcutaneous use, FDA label on DailyMed (version 20, published Jun 10, 2026; read Nov 18, 2026)
- RYBELSUS (semaglutide) tablets and OZEMPIC (semaglutide) tablets, for oral use, FDA label on DailyMed (version 14, published Aug 19, 2026; read Nov 18, 2026)
- WEGOVY (semaglutide) injection, for subcutaneous use, and WEGOVY (semaglutide) tablets, for oral use, FDA label on DailyMed (version 19, published Jun 30, 2026; read Nov 18, 2026)
- Drugs@FDA, NDA 209637 (Ozempic, the injection; application first approved 2017)
- Drugs@FDA, NDA 213051 (Ozempic, the tablets, added to the application by supplement 30 on Jan 30, 2026; application first approved 2019)
- Drugs@FDA, NDA 215256 (Wegovy, the injection; application first approved 2021)
- Drugs@FDA, NDA 218316 (Wegovy, the tablets; application first approved 2025)
PepVault is not affiliated with Novo Nordisk. Ozempic is a trademark of its owner. Wegovy is a trademark of its owner.